Strasbourg, France, May 22, 2026, 5:45 p.m. CET – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held ...

Good morning, and welcome to the Transgene conference call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Transgene website following ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock ...

Good day, and thank you for standing by. Welcome to the Transgene 2025 Annual Results and Prospective for 2026 Conference Call and Webcast. [Operator Instructions] Please be advised that today's ...

Earnings call Transgene reported 100% two-year disease-free survival in Phase I head and neck cancer patients treated with TG4050, reinforcing its strategic focus on the MiVAC platform. Financial ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, ...

Fundraising: EUR105 million raised in December 2025. Debt Conversion: EUR39 million debt converted into equity, making the company virtually debt-free. Cash Burn: Approximately EUR38.2 million in 2025 ...

Sanofi (EURONEXT: SAN and NYSE: SNY) and Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) announced today a collaboration agreement for the creation of a new state-of-the-art industrial platform ...

Transgene SA has received clinical trial application (CTA) approval from the French National Agency for the Safety of Medicines and Health Products (ANSM) to proceed with a phase I trial of TG-6050, a ...

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial reporting dates for 2017: About Transgene Transgene S.A. (Euronext: TNG), ...